No Data
No Data
Craig-Hallum Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating, Maintains Target Price $18
Craig-Hallum analyst Albert Lowe maintains $SKYE BIOSCIENCE INC(SKYE.US)$ with a buy rating, and maintains the target price at $18.According to TipRanks data, the analyst has a success rate of 50.0%
Skye Bioscience to Host Virtual KOL Event, "Metabolic Rewiring With CB1 Inhibition," on July 24th
SAN DIEGO, July 11, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of
Express News | Skye Bioscience Forms Clinical Advisory Board, Gathering Metabolic Disease Experts, Particularly In The Field Of Obesity
Skye Bioscience Establishes Metabolic Clinical and Scientific Advisory Board to Support Development of Nimacimab
SAN DIEGO, July 11, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of
Craig-Hallum Initiates SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating, Announces Target Price $18
Craig-Hallum analyst Albert Lowe initiates coverage on $SKYE BIOSCIENCE INC(SKYE.US)$ with a buy rating, and sets the target price at $18.According to TipRanks data, the analyst has a success rate
Craig-Hallum Initiates Skye Bioscience at Buy With $18 Price Target
12:09 PM EDT, 07/09/2024 (MT Newswires) -- Craig-Hallum Initiates Skye Bioscience at Buy With $18 Price TargetPrice: 5.98, Change: -0.17, Percent Change: -2.76
Skinny bulldogOP : Look at the other company in the same industry you will know. The problem is, how high it can go.